MX2022015622A - Compuestos de dihidroquinolin sulfonamida de ciclopropilo. - Google Patents

Compuestos de dihidroquinolin sulfonamida de ciclopropilo.

Info

Publication number
MX2022015622A
MX2022015622A MX2022015622A MX2022015622A MX2022015622A MX 2022015622 A MX2022015622 A MX 2022015622A MX 2022015622 A MX2022015622 A MX 2022015622A MX 2022015622 A MX2022015622 A MX 2022015622A MX 2022015622 A MX2022015622 A MX 2022015622A
Authority
MX
Mexico
Prior art keywords
compounds
dihydroquinoline
cyclopropyl
sulfonamide compounds
formula
Prior art date
Application number
MX2022015622A
Other languages
English (en)
Inventor
Isaac E Marx
Wei Zhao
Benjamin C Milgram
John Stellwagen
Alan H Cherney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022015622A publication Critical patent/MX2022015622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I, (ver Fórmula) (I); un enantiómero, diastereoisómero, atropisómero del mismo, una mezcla de los mismos, o una sal farmacéuticamente aceptable del mismo, que inhibe los canales de sodio activados por voltaje, en particular NaV1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen los compuestos de la presente invención. También se proporciona además una preparación atropi-selectiva de dichos compuestos de Fórmula (I), y un producto intermedio de los mismos.
MX2022015622A 2020-06-10 2021-06-10 Compuestos de dihidroquinolin sulfonamida de ciclopropilo. MX2022015622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036999P 2020-06-10 2020-06-10
PCT/US2021/036894 WO2021252818A1 (en) 2020-06-10 2021-06-10 Cyclopropyl dihydroquinoline sulfonamide compounds

Publications (1)

Publication Number Publication Date
MX2022015622A true MX2022015622A (es) 2023-01-11

Family

ID=76845312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015622A MX2022015622A (es) 2020-06-10 2021-06-10 Compuestos de dihidroquinolin sulfonamida de ciclopropilo.

Country Status (10)

Country Link
US (2) US20230234948A1 (es)
EP (1) EP4164748A1 (es)
JP (1) JP2021195367A (es)
AR (1) AR122593A1 (es)
AU (1) AU2021289741A1 (es)
CA (1) CA3183814A1 (es)
MX (1) MX2022015622A (es)
TW (1) TW202214587A (es)
UY (1) UY39264A (es)
WO (1) WO2021252818A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AR129116A1 (es) 2022-04-22 2024-07-17 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4412994A (en) 1980-04-24 1983-11-01 Interx Research Corporation Mannich-base hydroxamic acid prodrugs, compositions and use
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
AR103833A1 (es) * 2015-03-02 2017-06-07 Amgen Inc Compuestos bicíclicos de sulfonamida cetona
WO2017106871A1 (en) * 2015-12-18 2017-06-22 Amgen Inc. Alkyl dihydroquinoline sulfonamide compounds
MA44066A (fr) * 2015-12-18 2018-10-24 Amgen Inc Composés sulfonamides de dihydroquinoline d'alcynyle

Also Published As

Publication number Publication date
UY39264A (es) 2021-12-31
TW202214587A (zh) 2022-04-16
EP4164748A1 (en) 2023-04-19
CA3183814A1 (en) 2021-12-16
JP2021195367A (ja) 2021-12-27
US20210387977A1 (en) 2021-12-16
AR122593A1 (es) 2022-09-21
US11807634B2 (en) 2023-11-07
AU2021289741A1 (en) 2022-12-22
WO2021252818A1 (en) 2021-12-16
US20230234948A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
MX2022015622A (es) Compuestos de dihidroquinolin sulfonamida de ciclopropilo.
CR20220631A (es) Compuestos de dihidroquinolinsulfonamida de ciclobutilo
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
PH12017501570B1 (en) Bicyclic ketone sulfonamide compounds
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
RU2685502C2 (ru) Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
MX2022015659A (es) Compuesto de alquenil pirimidina, metodo de preparacion del mismo y aplicacion del mismo.
MX2022008931A (es) Composiciones farmaceuticas y sus usos.
WO2024050431A3 (en) Tapinarof and analogs thereof for use in treating ahr mediated diseases